These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 25275557)
61. Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. Funk EK; Shaffer A; Shivakumar B; Sneller M; Polis MA; Masur H; Heytens L; Nelson A; Kwan R; Kottilil S; Kohli A AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1190-4. PubMed ID: 23701022 [TBL] [Abstract][Full Text] [Related]
62. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. Bedimo R; Kang M; Tebas P; Overton ET; Hollabaugh K; McComsey G; Bhattacharya D; Evans C; Brown TT; Taiwo B AIDS Res Hum Retroviruses; 2016 Apr; 32(4):325-8. PubMed ID: 26499270 [TBL] [Abstract][Full Text] [Related]
63. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. Aparicio E; Parera M; Franco S; Pérez-Alvarez N; Tural C; Clotet B; Martínez MA PLoS One; 2010 Oct; 5(10):e13771. PubMed ID: 21048934 [TBL] [Abstract][Full Text] [Related]
64. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956 [TBL] [Abstract][Full Text] [Related]
65. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150 [TBL] [Abstract][Full Text] [Related]
66. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. Petersen T; Lee YJ; Osinusi A; Amorosa VK; Wang C; Kang M; Matining R; Zhang X; Dou D; Umbleja T; Kottilil S; Peters MG AIDS Res Hum Retroviruses; 2016 Jul; 32(7):660-7. PubMed ID: 26974581 [TBL] [Abstract][Full Text] [Related]
67. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. Núñez M; Mariño A; Miralles C; Berdún MA; Sola J; Hernandez-Burruezo JJ; Galindo MJ; Barreiro P; Martin-Carbonero L; Soriano V J Acquir Immune Defic Syndr; 2007 Aug; 45(4):439-44. PubMed ID: 17468669 [TBL] [Abstract][Full Text] [Related]
68. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330 [TBL] [Abstract][Full Text] [Related]
69. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ; Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631 [TBL] [Abstract][Full Text] [Related]
70. HIV and hepatitis C virus coinfection: bad bedfellows. Schooley RT Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454 [TBL] [Abstract][Full Text] [Related]
71. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435 [TBL] [Abstract][Full Text] [Related]
72. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Klein MB; Cooper C; Brouillette MJ; Sheehan NL; Benkelfat C; Annable L; Weston F; Kraus D; Singer J; Contemp Clin Trials; 2008 Jul; 29(4):617-30. PubMed ID: 18262853 [TBL] [Abstract][Full Text] [Related]
73. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067 [TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [TBL] [Abstract][Full Text] [Related]
75. HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. Quesnel-Vallières M; Lemay M; Lapointe N; Martin SR; Soudeyns H J Clin Virol; 2008 Oct; 43(2):236-40. PubMed ID: 18707918 [TBL] [Abstract][Full Text] [Related]
76. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. Rivero-Juarez A; Lopez-Cortes LF; Camacho A; Caruz A; Torres-Cornejo A; Martinez-Dueñas L; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A AIDS; 2013 Jul; 27(12):1941-7. PubMed ID: 23917425 [TBL] [Abstract][Full Text] [Related]
77. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients. Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976 [TBL] [Abstract][Full Text] [Related]
78. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. Klein MB; Lee T; Brouillette MJ; Sheehan NL; Walmsley S; Wong DK; Conway B; Hull M; Cooper C; Haidar S; Vezina S; Annable L; Young S; Zubyk W; Singer J HIV Clin Trials; 2014; 15(4):161-75. PubMed ID: 25143025 [TBL] [Abstract][Full Text] [Related]
79. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin. Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894 [TBL] [Abstract][Full Text] [Related]
80. Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV. Mallolas J; Laguno M Expert Rev Anti Infect Ther; 2008 Jun; 6(3):281-9. PubMed ID: 18588492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]